… sacubitril/valsartan in HF and patient selection perspectives In this section, we will discuss
the profile of sacubitril/valsartan in HF with regards to patient … Registry data on HFrEF patients …

… When selecting initial patients to prescribe sacubitril/valsartan, clinicians should ensure
their characteristics be similar to individuals in PARADIGM-HF [8] and consistent with the …

… ,13, 14 and only limited data are available, from small cohorts, regarding the initiation of
sacubitril/valsartan in non-selected hospitalized patients.15, 16 We have confirmed that our …

… has convincingly proven its benefit in reducing heart failure hospitalisation and cardiovascular
mortality in selected patients with HFrEF in the PARADIGM-HF study [Citation1]. However, …

… We selected patients eligible for sacubitril–valsartan treatment by applying the
PARADIGM-HF enrolment criteria on the Umeå heart failure population (Figure 1A). Of the 401 …

… selection of tolerant patients. For instance, the reported dose of 375 ± 75 mg sacubitril/valsartan
leaves out the 19.8% of patients … the trial and the 2079 patients excluded during the run-…

… We considered patients to be on sacubitril/valsartan if they … patients with a contraindication
to sacubitril/valsartan and … The study design may select a specific population of HFrEF patients…

… In PARADIGM-HF, patients had to fulfil selection criteria for both screening and randomization,
but symptom, natriuretic peptide, and LVEF criteria only had to be fulfilled at screening, …

… Whilst not undermining the value of sacubitril–valsartan in selected patients, this study
suggests that achieving an improvement of survival in a greater proportion of HF …

… in 19–76% of the selected publications and suggested more … of European HFrEF patients
given sacubitril-valsartan have … on the type of patients treated with sacubitril-valsartan in real-…